Clinical trials: Carcinoma Cervix
Cervix Carcinoma
Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix
The goal of this clinical research study is to learn if it is possible to get high-resolution microendoscopy (HRME) images of AIS tissue and/or tissue from microinvasive carcinoma right before a biopsy of the cervix.
- Trial name
- NCT02206048
- Testing
- Proflavine, High-Resolution Microendoscopy (HRME) Imaging
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Carcinoma, Human Papillomavirus Infection
Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia
This trial studies how well a multilevel human papillomavirus (HPV) self-testing intervention works in increasing cervical cancer screening among women in Appalachia.
- Trial name
- NCT04411849
- Testing
- Best Practice, HPV Self-Collection, Informational Intervention
- Where
- 4 sites in United States
- Volunteers
- 802 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cervical Cancer
Promoting Cervical Cancer Screening for Emergency Department Patients
The purpose of this study is to learn methods to encourage women to get recommended cervical cancer screening. Cervical cancer screening is an important part of cervical cancer prevention.
- Trial name
- NCT03483610
- Testing
- Provider Referral, Text Messaging
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- University of Rochester
Cervical Cancer Screening
Cervical Cancer Self-Collection for Southeast Asian Immigrant and Refugee Women
The primary purpose of this study is to determine whether educational workshops paired with self-collected high-risk human papillomaviruses (hrHPV) screening will increase participation in cervical cancer screening among…
- Trial name
- NCT05286749
- Testing
- Workshop plus Clinician-Collected Cervical Swab, Workshop plus Participant-Collected Cervical Swab, HPV testing on Participant-Collected Cervical Swab Samples
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Cervical Cancer
Using CHWs or Mailing Self Sampling Home Tests to Increase Cervical Cancer Screening in South Florida
The study will test the significance of community health worker (CHW) participation by comparing self-sampling provided by a community health worker and self-sampling provided by mail.
- Trial name
- NCT02202109
- Testing
- CHW and Self-sampling for Cervical Cancer, Mailed Self Sampler
- Where
- United States
- Volunteers
- 602 people
- Sponsor
- University of Miami
Cervical Cancer
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
This is an open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccines delivered by electroporation (EP) to female participants with HPV-16 and/or 18-positive cervical carcinoma.
- Trial name
- NCT02172911
- Testing
- INO-3112, CELLECTRA™-5P
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Cancer
Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women
The purpose of this trial is to determine whether mailing in-home human papillomavirus (HPV) screening kits is effective in increasing uptake of cervical cancer screening and early detection and treatment of cervical neoplasia in…
- Trial name
- NCT02005510
- Testing
- Mailed in-home high-risk HPV testing kit, Usual care
- Where
- United States
- Volunteers
- 19,851 people
- Sponsor
- University of Washington
HPV
Self-sampling for Human Papillomavirus (HPV) Among Patients Receiving Colposcopy
This study seeks to compare the accuracy and acceptability of HPV testing self-sampling kit and standard clinician-sampling for HPV testing.
- Trial name
- NCT04585243
- Testing
- Evalyn Brush
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Milton S. Hershey Medical Center
Infections, Papillomavirus
Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females
This Post Marketing Surveillance (PMS) will collect safety data on the use of GSK Biologicals' human papillomavirus (HPV) vaccine in the local target population of females as per the regulations of the Korean Food and Drugs…
- Trial name
- NCT01101542
- Testing
- Cervarix., Data collection
- Where
- 2 sites in South Korea
- Volunteers
- 3,091 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cancer of the Cervix, Cervical Neoplasms
Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)
The purpose of this study is to determine the maximum tolerated dose of integrated boost radiation therapy when given with concurrent chemotherapy (cisplatin).
- Trial name
- IDEAL (NCT01627288)
- Testing
- Boost radiation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Duke University
Cervical Cancer
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00980954
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 125 sites in United States, Canada and 2 more
- Volunteers
- 236 people
- Sponsor
- Radiation Therapy Oncology Group
HIV Infections, Human Papillomavirus Infection
Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV
This is a cross-sectional, observational study of high-risk HPV status, cervical cytology and HPV vaccine uptake and response in young women with perinatally acquired HIV.
- Conditions
- HIV Infections, Human Papillomavirus Infection, Cervical Cancer
- Trial name
- SHiP (NCT04587050)
- Testing
- Human papillomavirus testing, Cervical cytology, HPV serology
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Imperial College London
Human Papillomavirus Infection
Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System
The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.
- Trial name
- NCT00973362
- Testing
- APTIMA HPV Assay, FDA-Approved HPV DNA Test
- Where
- 17 sites in United States
- Volunteers
- 12,896 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Infections, Papillomavirus, Papillomavirus Vaccines
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine (HPV) vaccine or control.
- Trial name
- NCT00294047
- Testing
- Cervarix
- Where
- 75 sites in United States, Australia and 10 more
- Volunteers
- 5,752 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Carcinoma, Cervical Adenocarcinoma
Ixabepilone to Treat Cervical Cancer
Background: Ixabepilone is a member of the class of drugs called epothilones. These drugs interfere with the ability of cancer cells to replicate.
- Conditions
- Cervical Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Carcinoma, Non-SquamousType
- Trial name
- NCT00924066
- Testing
- Ixempra (Ixabepilone (BMS-247550) )
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with…
- Trial name
- NCT03674567
- Testing
- FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
- Where
- 35 sites in United States, Australia and 4 more
- Volunteers
- 323 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
High Risk Cervical Cancer, Advanced Cervical Cancer
Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer
Locally advanced cervical cancer at higher risk for recurrence (HRLACC) following concurrent chemotherapy and radiation therapy. This is a group of participants with a significant unmet need.
- Trial name
- AIM2CERV (NCT02853604)
- Testing
- ADXS11-001
- Where
- 117 sites in United States, Argentina and 12 more
- Volunteers
- 110 people
- Sponsor
- Advaxis, Inc.
Cervical Cancer, Genital Warts
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.
- Trial name
- NCT00092495
- Testing
- V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 3,055 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Paclitaxel and cisplatin may increase the effectiveness of radiation therapy by making the tumor cells more sensitive to the radiation.
- Trial name
- NCT00003377
- Testing
- cisplatin, paclitaxel, brachytherapy
- Where
- 13 sites in United States
- Volunteers
- 29 people
- Sponsor
- Gynecologic Oncology Group
Infections, Papillomavirus
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. The infection of the cervix by certain oncogenic types of HPV, if not cleared, can lead to cervical cancer in women.
- Trial name
- NCT00485732
- Testing
- HPV-16/18 VLP/AS04 vaccine (Cervarix TM)
- Where
- 6 sites in South Korea
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline